About us
Lumobiotics develops light-controllable peptide drugs as safe cytolytic agents for treatment of solid cancers and localized infectious diseases. We are dedicated to fostering the development of chemotherapeutic s based on the technology platform, utilizing molecular photoswitches. As a university Spin-off we perform rigorous science translating into societal benefit.
Management team
Dr Tim Schober
Co-founder
CEO
CEO
Kateryna Tolmachova
Co-founder
Dr Sergii Afonin
Co-founder
COO
COO
Scientific advisors
Prof Igor Komarov
Co-founder
Scientific advisor
Scientific advisor
Dr Oleg Babii
Co-founder
Scientific advisor
Scientific advisor
External advisors
Immuno-oncology discovery program is being implemented under scientific advise of Prof Viktor Umansky (German Cancer Research Center (DKFZ), Heidelberg, Germany)
